869 results on '"ESSEBAG, VIDAL"'
Search Results
152. VALUE OF AORTIC PLAQUE IN PREDICTING LEFT ATRIAL APPENDAGE THROMBUS IN LOW RISK PATIENTS UNDERGOING ELECTROPHYSIOLOGICAL PROCEDURES
153. A WIDE COMPLEX TACHYCARDIA DURING PREGNANCY
154. Predicting response to cardiac resynchronization therapy: Use of strict left bundle branch block criteria
155. Atrial flutter and embolic risk: The relationship between atrial flutter cycle length and left atrial appendage function
156. Rationale and design of the randomized prospective ATLAS study: Avoid Transvenous Leads in Appropriate Subjects
157. A randomized clinical trial of early invasive intervention for atrial fibrillation (EARLY-AF) - methods and rationale
158. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure
159. Long-term risk of stroke and bleeding post-atrial fibrillation ablation
160. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2)
161. Left atrial appendage isolation in atrial fibrillation catheter ablation: A meta‐analysis
162. Pulmonary embolism after electrophysiology procedures: Incidence from a single centre registry
163. Defining the pattern of initiation of monomorphic ventricular tachycardia using the beat-to-beat intervals recorded on implantable cardioverter defibrillators from the RAFT study: A computer-based algorithm
164. Differentiating Ventricular From Supraventricular Arrhythmias Using the Postpacing Interval After Failed Antitachycardia Pacing
165. Canadian Registry of Implantable Electronic Device Outcomes: Longer-term follow-up of the Riata lead under advisory
166. QUALITY OF LIFE POST AF ABLATION AND RELATIONSHIP TO OUTCOME AND AF BURDEN
167. Mexiletine or catheter ablation after amiodarone failure in the VANISH trial
168. PP34 A Cost-Utility Analysis Of The Syncope: Pacing Or Recording Trial
169. Cost Effectiveness of Continued-Warfarin Versus Heparin-Bridging Therapy During Pacemaker and Defibrillator Surgery
170. Catheter ablation for the treatment of atrial fibrillation is associated with a reduction in health care resource utilization
171. Pattern of initiation of monomorphic ventricular tachycardia and implications on tachycardia mechanism
172. In Memoriam: Mark E. Josephson, MD
173. PREDICTING ELECTROCARDIOGRAPHIC AND ECHOCARDIOGRAPHIC RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY: THE USE OF STRICT LEFT BUNDLE BRANCH BLOCK CRITERIA
174. Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials
175. Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation
176. Canadian Registry of Implantable Electronic Device Outcomes
177. Intracardiac echo-facilitated 3D electroanatomical mapping of ventricular arrhythmias from the papillary muscles: assessing the ‘fourth dimension’ during ablation
178. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs
179. Simple risk stratification score for prognosis of syncope
180. Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial
181. Implications of Frailty in Elderly Patients With Electrophysiological Conditions
182. 176-18: Impact of second generation cryoballoon ablation in paroxysmal atrial fibrillation patients: AF symptoms and quality of life at 12 months post ablation from the STOP-AF post approval study
183. 176-19: Second generation cryoballoon ablation in paroxysmal atrial fibrillation patients: 12 month safety and efficacy from the STOP-AF post approval study
184. Management of antithrombotic therapy during cardiac implantable device surgery
185. THE IMPACT OF BODY WEIGHT ON ADVERSE OUTCOMES WITH NOVEL ORAL ANTICOAGULANTS AND WARFARIN: PRELIMINARY RESULTS FROM THE INTEGRATE STUDY
186. MULTI-FACETED KNOWLEDGE TRANSLATION TO IMPROVE CARE OF PATIENTS WITH ATRIAL FIBRILLATION: PRELIMINARY RESULTS FROM THE INTEGRATE/FACILITER PROJECTS
187. CATHETER ABLATION FOR THE TREATMENT OF ATRIAL FIBRILLATION REDUCES HEALTH CARE RESOURCE UTILIZATION
188. Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection
189. Dabigatran use in elderly patients with atrial fibrillation
190. Recent advances in ablation of ventricular tachycardia associated with structural heart disease
191. Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials
192. The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
193. Quality of life with ablation or medical therapy for ventricular arrhythmias: A substudy of VANISH.
194. Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease).
195. Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design
196. The Impact of Duration of Atrial Fibrillation Recurrences on Measures of Health‐Related Quality of Life and Symptoms
197. The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines
198. Ablation of an atriofascicular accessory pathway with a zero-fluoroscopy procedure
199. Temporal trends and sex differences in pulmonary vein isolation for patients with atrial fibrillation
200. Prognostic value of pulmonary vein size in prediction of atrial fibrillation recurrence after pulmonary vein isolation: a cardiovascular magnetic resonance study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.